Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT.

Int J Radiat Oncol Biol Phys. 2019 Aug 13. pii: S0360-3016(19)33641-7. doi: 10.1016/j.ijrobp.2019.08.008. [Epub ahead of print]

2.

Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.

Lewis SL, Patel P, Song H, Freedland SJ, Bynum S, Oh D, Palta M, Yoo D, Oleson J, Salama JK.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):605-11. doi: 10.1016/j.ijrobp.2015.11.025. Epub 2015 Dec 2.

PMID:
26867889
3.

Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate.

Giacinti S, Carlini P, Roberto M, Bassanelli M, Strigari L, Pavese F, Aschelter AM, Felici A, Valeriani M, Cognetti F, Marchetti P.

Anticancer Drugs. 2017 Jan;28(1):110-115.

PMID:
27763885
4.

High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.

Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M.

Brachytherapy. 2017 Mar - Apr;16(2):299-305. doi: 10.1016/j.brachy.2016.11.002. Epub 2016 Dec 10.

PMID:
27965117
5.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2018 Sep 6. doi: 10.1007/s00345-018-2477-2. [Epub ahead of print]

PMID:
30191396
6.

Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.

Matzkin H, Chen J, Agai R, Ziv-Baran T, Mabjeesh NJ.

PLoS One. 2019 Apr 19;14(4):e0215582. doi: 10.1371/journal.pone.0215582. eCollection 2019.

7.

Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens.

Tandberg DJ, Oyekunle T, Lee WR, Wu Y, Salama JK, Koontz BF.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):396-405. doi: 10.1016/j.ijrobp.2018.02.002. Epub 2018 Feb 8.

PMID:
29559284
8.

Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome.

Riva G, Marvaso G, Augugliaro M, Zerini D, Fodor C, Musi G, De Cobelli O, Orecchia R, Jereczek-Fossa BA.

Ecancermedicalscience. 2017 Nov 30;11:786. doi: 10.3332/ecancer.2017.786. eCollection 2017.

9.

The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.

Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.

Can J Urol. 2017 Feb;24(1):8656-8662.

PMID:
28263132
10.

Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.

Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox JL, Mah D, Garg MK, Han-Chih Chang J, Lee NY.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):386-95. doi: 10.1016/j.ijrobp.2016.02.036. Epub 2016 Feb 17.

11.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
12.

American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy-A systematic literature review.

Keyes M, Merrick G, Frank SJ, Grimm P, Zelefsky MJ.

Brachytherapy. 2017 Mar - Apr;16(2):245-265. doi: 10.1016/j.brachy.2016.11.017. Epub 2017 Jan 16. Review.

13.

Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.

Jolnerovski M, Salleron J, Beckendorf V, Peiffert D, Baumann AS, Bernier V, Huger S, Marchesi V, Chira C.

Radiat Oncol. 2017 Jun 16;12(1):99. doi: 10.1186/s13014-017-0839-3.

14.

Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J.

Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):34-40. Epub 2007 Feb 7.

PMID:
17289288
15.

Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer.

Muldermans JL, Romak LB, Kwon ED, Park SS, Olivier KR.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):696-702. doi: 10.1016/j.ijrobp.2016.01.032. Epub 2016 Jan 29.

16.

Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.

McKay RR, Gray KP, Hayes JH, Bubley GJ, Rosenberg JE, Hussain A, Kantoff PW, Taplin ME.

Cancer. 2015 Aug 1;121(15):2603-11. doi: 10.1002/cncr.29398. Epub 2015 Apr 22.

17.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Gravis G, Boher JM, Joly F, Soulié M, Albiges L, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Culine S, Mourey L, Beuzeboc P, Habibian M, Oudard S, Fizazi K; GETUG.

Eur Urol. 2016 Aug;70(2):256-62. doi: 10.1016/j.eururo.2015.11.005. Epub 2015 Nov 21.

PMID:
26610858
18.

CLINICAL OUTCOMES OF EXTERNAL-BEAM RADIOTHERAPY COMBINED WITH NEOADJUVANT ANDROGEN DEPRIVATION THERAPY FOR HIGH-RISK PROSTATE CANCER.

Okada T, Takayama K, Kokubo M, Kono Y, Matsumoto K, Sumiyoshi T, Masuda N, Shiraishi Y, Negoro H, Utsunomiya N, Tsunemori H, Okubo K, Segawa T, Moroi S, Muguruma K, Kawakita M.

Nihon Hinyokika Gakkai Zasshi. 2016;107(3):162-169. doi: 10.5980/jpnjurol.107.162. Japanese.

19.

Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.

Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH.

Gynecol Oncol. 2018 Jan;148(1):132-138. doi: 10.1016/j.ygyno.2017.10.017. Epub 2017 Oct 28.

PMID:
29089122
20.

Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy.

Beck M, Wust P, Barelkowski T, Kaul D, Thieme AH, Wecker S, Wlodarczyk W, Budach V, Ghadjar P.

Radiat Oncol. 2017 Aug 10;12(1):125. doi: 10.1186/s13014-017-0862-4.

Supplemental Content

Support Center